Retina

Study finds low-vision rehab boosts daily function and quality of life, but exposes gaps in long-term data and diverse research.

The ongoing GARDian3 study is designed to assess whether a single subretinal administration of OCU410ST can slow structural disease progression in patients with ABCA4-associated retinopathy.

Kodiak Sciences has indicated plans to submit a biologics license application (BLA) to the US Food and Drug Administration.

Q1 2026 eye-care roundup: first dual-agent presbyopia drop, new EDOF IOL, wet AMD phase 3 win, and gene-therapy advances.

Luminopia, formerly cleared by the FDA for amblyopia in children, has begun its foray into IXT with positive data from a preliminary investigation.

Key regulatory filings, phase 3 readouts, and trial enrollments to watch through June 30.

New MLSDT functional vision test tracks advanced retinitis pigmentosa better than acuity, supporting future gene and optogenetic therapy endpoints.

DSP-3077 is being evaluated by Sumitomo Pharma in an ongoing phase 1/2 study (NCT06891885), designed to assess safety, tolerability, and preliminary efficacy in patients with RP.

Prof. Sobha Sivaprasad discusses why GA's multistage nature demands a broader therapeutic approach—and what evidence will shape clinical decision-making.

Prof. Anat Loewenstein questioned whether treat-and-extend will remain the preferred strategy as longer-acting therapies emerge.

Andrew G. Lee, MD, presents the “no” perspective on whether GLP-1 agonists cause non-arteritic anterior ischemic optic neuropathy, arguing that current evidence shows association but not proven causation.

Aflibercept briefly reverses severe ROP in tiny preemies, yet nearly half relapse within weeks—prompting laser rescue and renewed safety questions.

See which ophthalmology surgery centers earn US News’ 2026 high-performing badge, where they cluster, and why complication rates drop 40%.

The trial, sponsored by ONL Therapeutics, aims to enrol approximately 324 patients across sites in Europe, the United States, and Canada.

About 90% of patients are female with obesity and potential hormonal drivers

The 3rd Winterthur Ophthalmology Symposium in Winterthur, Switzerland, on 12–13 March 2026 will feature plenary talks, hands-on workshops, satellite sessions, poster presentations, and a gala honoring the Otto Haab Medal.

The phase 2a study looks at retinal vascular diseases, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).

FDA greenlights first human trial of SVT-001, a regenerative cell therapy aiming to restore vision for patients with rare familial drusen.

The company describes liMeliGhT as a 1-year clinical trial that will support the Biologics License Application (BLA) filing for OCU400 and potential approval in 2027.

Gene and cell therapies plus AI imaging tools accelerate breakthroughs for rare retinal diseases, spotlighting new trials for RP and Stargardt patients.

A recent nonrandomized trial has demonstrated toric IOLs’ efficacy in providing long-term visual outcomes, reducing amblyopia compared to non-toric lenses.

PULSAR post-hoc finds aflibercept 8 mg matches 2 mg for PCV, offering 12–16-week dosing and reduced injection burden.

A recent study highlights the efficacy of the FAi implant in patients with NIU-related macular edema, improving BCVA and reducing choroidal thickness.